CMMBChemomab Therapeutics Ltd.

CMMB Stock Price, Valuation & Chart | Chemomab Therapeutics Ltd.

Compare

$2.730+0.00 (+0.00%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CMMB intrinsic value CMMB calculated fair value vs price

Overview Financials Dividends Ratios

CMMB Historical price chart

CMMB Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization16.80M

PE Ratio-1.69

EPS-1.62

Trading Volume41.31K

Today's High/Low2.84/2.73

Dividend Yield0.00

52 Week High/Low3.58/1.35

Shares Outstanding6.16M

CMMB Financial Statement

CMMB Analyst ratings

CMMB Analysis & performance metrics

CMMB Company profile

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical…

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The…

CMMB Management team

Name

Position

Sigal Fattal CPA, M.B.A.CFO

Chief Financial Officer

David M. Weiner M.D.

Interim Chief Medical Officer

Adi Mor George Ph.D.CEO

Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director

Barbara Lindheim

Consulting Vice President of Investor & Public Relations, Strategic Communications

Jack Lawler

Chief Development Officer

Matthew B. Frankel M.B.A., M.D.

Chief Medical Officer & Vice President of Drug Development

Name

Position

Sigal Fattal CPA, M.B.A.CFO

Chief Financial Officer

David M. Weiner M.D.

Interim Chief Medical Officer

Adi Mor George Ph.D.CEO

Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director

Barbara Lindheim

Consulting Vice President of Investor & Public Relations, Strategic Communications

Jack Lawler

Chief Development Officer

Matthew B. Frankel M.B.A., M.D.

Chief Medical Officer & Vice President of Drug Development

Management Team

Sigal Fattal CPA, M.B.A.CFO

Chief Financial Officer

David M. Weiner M.D.

Interim Chief Medical Officer

Adi Mor George Ph.D.CEO

Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director

Barbara Lindheim

Consulting Vice President of Investor & Public Relations, Strategic Communications

Jack Lawler

Chief Development Officer

Matthew B. Frankel M.B.A., M.D.

Chief Medical Officer & Vice President of Drug Development

Management

Sigal Fattal CPA, M.B.A.CFO

Chief Financial Officer

David M. Weiner M.D.

Interim Chief Medical Officer

Adi Mor George Ph.D.CEO

Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director

Barbara Lindheim

Consulting Vice President of Investor & Public Relations, Strategic Communications

Jack Lawler

Chief Development Officer

Matthew B. Frankel M.B.A., M.D.

Chief Medical Officer & Vice President of Drug Development

Total 6 executives

CMMB Frequently asked questions

What is Chemomab Therapeutics Ltd. (CMMB) Stock Price?

Current stock price of Chemomab Therapeutics Ltd. (CMMB) stock is $2.730. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Chemomab Therapeutics Ltd. (CMMB) stock is 41.31K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Chemomab Therapeutics Ltd. (CMMB) stock price going up or down today?

The stock price of Chemomab Therapeutics Ltd. (CMMB) can change with earnings, company news, and overall market sentiment. Chemomab Therapeutics Ltd. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Chemomab Therapeutics Ltd. stock expensive at its current price?

Whether Chemomab Therapeutics Ltd. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CMMB on this page is -1.69. EPS on this page is -1.62. Compare those figures with peers and growth expectations before deciding if the current Chemomab Therapeutics Ltd. price is justified.

How has the stock price of Chemomab Therapeutics Ltd. (CMMB) performed historically?

Historical performance for Chemomab Therapeutics Ltd. (CMMB) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CMMB reacted to past earnings and market events.

Should I buy Chemomab Therapeutics Ltd. (CMMB) stock, at this price?

Buying Chemomab Therapeutics Ltd. (CMMB) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.